Evidence map›Paper›PMID 28581528›Full record

ArticleOncogene2017

DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.

C Pistore, E Giannoni, T Colangelo, F Rizzo, E Magnani, L Muccillo, G Giurato, M Mancini, S Rizzo, M Riccardi and 12 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 103 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Epigenetic regulation of cancer stemness.Signal transduction and targeted therapy · 2025
    Review
  8. Review
  9. Lactate and lactylation in cancer.Signal transduction and targeted therapy · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Factors Determining Epithelial-Mesenchymal Transition in Cancer Progression.International journal of molecular sciences · 2024
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

C PistoreDepartment of Biotechnology and Life Sciences, University of Insubria, Busto Arsizio (VA), Italy.
E GiannoniDepartment of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy.
T ColangeloDepartment of Sciences and Technologies, University of Sannio, Benevento, Italy.
F RizzoLaboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Schola Medica Salernitana', University of Salerno, Baronissi (SA), Italy.
E MagnaniDepartment of Biotechnology and Life Sciences, University of Insubria, Busto Arsizio (VA), Italy.
L MuccilloDepartment of Sciences and Technologies, University of Sannio, Benevento, Italy.
G GiuratoLaboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Schola Medica Salernitana', University of Salerno, Baronissi (SA), Italy.
M ManciniDepartment of Biotechnology and Life Sciences, University of Insubria, Busto Arsizio (VA), Italy.
S RizzoDepartment of Biotechnology and Life Sciences, University of Insubria, Busto Arsizio (VA), Italy.
M RiccardiDepartment of Biotechnology and Life Sciences, University of Insubria, Busto Arsizio (VA), Italy.
N SahnaneAnatomic Pathology Unit, Department of Surgical and Morphologic Sciences, University of Insubria, Varese, Italy.
V Del VescovoCentre for Integrative Biology, University of Trento, Trento, Italy.
K KishoreCentre for Genomic Sciences, Italian Institute of Technology, Milan, Italy.
M MandruzzatoDepartment of Biotechnology and Life Sciences, University of Insubria, Busto Arsizio (VA), Italy.
F MacchiDepartment of Biotechnology and Life Sciences, University of Insubria, Busto Arsizio (VA), Italy.
M PelizzolaCentre for Genomic Sciences, Italian Institute of Technology, Milan, Italy.ORCID 0000-0001-6672-9636
M A DentiCentre for Integrative Biology, University of Trento, Trento, Italy.
D FurlanAnatomic Pathology Unit, Department of Surgical and Morphologic Sciences, University of Insubria, Varese, Italy.
A WeiszLaboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Schola Medica Salernitana', University of Salerno, Baronissi (SA), Italy.
V ColantuoniDepartment of Sciences and Technologies, University of Sannio, Benevento, Italy.
P ChiarugiDepartment of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy.
I M BonapaceDepartment of Biotechnology and Life Sciences, University of Insubria, Busto Arsizio (VA), Italy.
University of Insubria · ITUniversity of Salerno · ITUniversity of Sannio · ITItalian Institute of Technology · ITUniversity of Florence · ITUniversity of Trento · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Widespread genome hypo-methylation and promoter hyper-methylation of epithelium-specific genes are hallmarks of stable epithelial-to-mesenchymal transition (EMT), which in prostate cancer (PCa) correlates with castration resistance, cancer stem cells generation, chemoresistance and worst prognosis. Exploiting our consolidated 'ex-vivo' system, we show that cancer-associated fibroblasts (CAFs) released factors have pivotal roles in inducing genome methylation changes required for EMT and stemness in EMT-prone PCa cells. By global DNA methylation analysis and RNA-Seq, we provide compelling evidence that conditioned media from CAFs explanted from two unrelated patients with advanced PCa, stimulates concurrent DNA hypo- and hyper-methylation required for EMT and stemness in PC3 and DU145, but not in LN-CaP and its derivative C4-2B, PCa cells. CpG island (CGI) hyper-methylation associates with repression of genes required for epithelial maintenance and invasion antagonism, whereas activation of EMT markers and stemness genes correlate with CGI hypo-methylation. Remarkably, methylation variations and EMT-regulated transcripts almost completely reverse qualitatively and quantitatively during MET. Unsupervised clustering analysis of the PRAD TCGA data set with the differentially expressed (DE) and methylated EMT signature, identified a gene cluster of DE genes defined by a CAF+ and AR- phenotype and worst diagnosis. This gene cluster includes the relevant factors for EMT and stemness, which display DNA methylation variations in regulatory regions inversely correlated to their expression changes, thus strongly sustaining the ex-vivo data. DNMT3A-dependent methylation is essential for silencing epithelial maintenance and EMT counteracting genes, such as CDH1 and GRHL2, that is, the direct repressor of ZEB1, the key transcriptional factor for EMT and stemness. Accordingly, DNMT3A knock-down prevents EMT entry. These results shed light on the mechanisms of establishment and maintenance of coexisting DNA hypo- and hyper-methylation patterns during cancer progression, the generation of EMT and cell stemness in advanced PCa, and may pave the way to new therapeutic implications.

Indexed as

Cell Transformation, NeoplasticDNA MethylationCancer-Associated FibroblastsCell Line, TumorCulture Media, ConditionedCytosineDNA (Cytosine-5-)-MethyltransferasesDNA, NeoplasmEpithelial CellsGene Expression Regulation, NeoplasticHumansMaleMesodermProstatic NeoplasmsStem CellsTranscriptional ActivationCulture Media, ConditionedCytosineDNA (Cytosine-5-)-MethyltransferasesDNA, Neoplasm

Identifiers

PMID28581528
OpenAlexW2623815087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.